Sleep Apnea Devices Market to Reach $22+ Billion by 2035, Growing at 4.61% CAGR | ResMed, Philips, LivaNova Among Key Players

Roots Analysis has released its latest intelligence report on the global sleep apnea devices market, valued at $13.5 billion in 2024 and forecast to expand at a compound annual growth rate of 4.61% through 2035. The report spans over 385 pages of market data, company profiles, clinical pipeline analysis, and segmented forecasts, covering the full spectrum from CPAP machines and oral appliances to implantable neurostimulators and drug therapies.

To explore the complete findings, request a free sample of the report at https://www.rootsanalysis.com/reports/sleep-apnea-devices-market/request-sample.html

Market Overview
Sleep apnea affects an estimated 1 billion people worldwide with mild to severe symptoms, yet a substantial share of those cases remain undiagnosed. The condition, which involves repeated interruptions in breathing during sleep, carries serious downstream health consequences including cardiovascular disease, metabolic disorders, and cognitive impairment. Obstructive sleep apnea accounts for the majority of diagnoses, while central sleep apnea and complex sleep apnea represent smaller but clinically significant subgroups.

The scale of unmet clinical need is sharpest in developed markets. In the United States, roughly 7% of the total population and 60% of adults aged 65 and above have obstructive sleep apnea. Europe is not far behind; approximately 90 million people, or 22.7% of the European population, experience moderate to severe OSA. These numbers are not static. Improved detection protocols, broader awareness campaigns, and the rising adoption of home sleep apnea testing devices are pulling more undiagnosed patients into formal care pathways, enlarging the addressable market.

From an investment standpoint, the sector has attracted close to $1.6 billion across the past four years. LivaNova alone raised $595 million through equity financing, earmarked to advance its neurostimulator device for sleep apnea treatment. Over 1,600 patents focused on sleep apnea have been granted or filed during the same period, concentrated primarily around device innovation.

Key Growth Drivers
Rising Disease Burden Across Age Groups. Sleep apnea prevalence climbs steadily with age, placing the condition at the intersection of global aging trends. With geriatric populations growing across North America, Europe, and Asia, the volume of patients requiring diagnosis and ongoing management will continue to build. Obesity, sedentary lifestyles, smoking, and alcohol consumption are compounding the risk profile across younger demographics as well.

Shift Toward Home-Based Diagnosis. Home sleep apnea testing devices now hold the largest share within the diagnostic segment. These devices offer a cost-effective and convenient alternative to laboratory polysomnography, reducing barriers to initial diagnosis. Payers and healthcare systems increasingly support at-home testing as a first-line option, accelerating device adoption outside clinical settings.

AI Integration and Wearable Technology. Samsung entered into a collaboration with Stanford Medicine in April 2025 to advance AI-driven sleep apnea detection through wearables, enhancing the accuracy of its Sleep Apnea monitoring feature. Incannex Healthcare partnered with the AASM Foundation in March 2026 to fund research targeting advances in OSA detection and management. These initiatives reflect a broader industry shift toward continuous, real-time monitoring that extends the market beyond episodic in-clinic treatment.

New Device Approvals Expanding Treatment Options. Nyxoah's Genio system received FDA approval in July 2025 as an implantable hypoglossal nerve stimulator for moderate to severe OSA. ProSomnus received FDA clearance in April 2026 for its RPMO2 oral appliance, targeted at patients who cannot tolerate CPAP therapy. Each new approval opens an additional patient segment and creates competitive pressure on established device categories.

Drug Therapy Pipeline Adding a New Dimension. Over 35 sleep apnea drug therapies are currently in clinical evaluation, either as monotherapies or in combination. Apnimed received FDA fast track designation for its oral pharmacologic combination, and Eli Lilly's tirzepatide received fast track designation for OSA treatment. A successful drug approval would shift market dynamics, creating new categories within a historically device-dominated space.

Market Segmentation
By product type, sleep apnea medical devices hold the highest share and will continue to lead through 2035, though drug therapies represent a fast-growing adjacent category. Within the diagnostic segment, home sleep apnea testing devices dominate over polysomnography, reflecting the preference for portable, at-home screening. In the therapeutic device segment, oral devices held the largest share in 2025 owing to their ease of use and patient comfort. Within positive airway pressure devices, CPAP machines account for close to 40% of the sub-segment market, with ResMed capturing approximately 48% of the total OSA devices market. By route of administration, subcutaneous therapies capture the highest share in 2025. Implantable devices represent the fastest-growing therapeutic category, supported by recent regulatory approvals and growing physician awareness.

To request quote of this report, please visit:
https://www.rootsanalysis.com/reports/sleep-apnea-devices-market/request-quote.html

Regional Insights
North America commands approximately 70% of the global sleep apnea devices market and is expected to retain that position through the forecast period. The United States benefits from well-developed reimbursement infrastructure, high clinical awareness, and a large installed base of CPAP users estimated at around 8 million. Roughly 50% of all sleep apnea device manufacturers worldwide are based in North America, with the US and Canada functioning as the primary hubs for product development and commercialization.

Asia-Pacific is the standout growth region, projected to expand at a CAGR of approximately 9% through 2035, well above the global average. Rising healthcare expenditure, growing middle-class populations with obesity-linked sleep disorders, and improving diagnostic infrastructure across China, India, Japan, and South Korea are all contributing to that acceleration. Europe holds a meaningful share of the global market, given its high prevalence rates, though growth is comparatively moderate relative to Asia-Pacific.

Competitive Landscape
The sleep apnea devices market features more than 110 companies, spanning large multinationals, mid-sized specialists, and early-stage innovators. Key players include ResMed, Philips, LivaNova, SomnoMed, Oventus Medical, Nihon Kohden, Nox Medical, Vyaire Medical, Drive DeVilbiss Healthcare, Löwenstein Medical, ZOLL Itamar, Wellue, Acurable, Advanced Brain Monitoring, Apnimed, Eli Lilly and Company, Incannex Healthcare, and Nyxoah, among others. Israel-based Appscent Medical is developing an AI-based contactless home care device for sleep apnea detection, representing the frontier of non-contact diagnostics.

The market is well-fragmented despite ResMed's leading share position. Competition centers on clinical differentiation, regulatory clearances, and the integration of digital health capabilities rather than price alone. The drug therapy pipeline introduces a potential new axis of competition, as pharmaceutical players from outside the traditional device space begin to encroach on the treatment market.

Browse Full Report Description + Research Methodology + Table of Content + Infographics here:
https://www.rootsanalysis.com/reports/sleep-apnea-devices-market.html

Contact Details
Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com
Website: https://www.rootsanalysis.com

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

This release was published on openPR.